Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Return on Sales (2020 - 2026)

Maxcyte has reported Return on Sales over the past 6 years, most recently at 0.02% for Q4 2025.

  • Quarterly Return on Sales rose 3.0% to 0.02% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.02% through Dec 2025, down 1.0% year-over-year, with the annual reading at 0.02% for FY2025, 1.0% down from the prior year.
  • Return on Sales was 0.02% for Q4 2025 at Maxcyte, up from 0.02% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.02% in Q4 2025 and troughed at 0.04% in Q4 2021.
  • The 5-year median for Return on Sales is 0.01% (2022), against an average of 0.01%.
  • Year-over-year, Return on Sales decreased -5bps in 2021 and then grew 4bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 0.04% in 2021, then skyrocketed by 95bps to 0.0% in 2022, then surged by 517bps to 0.01% in 2023, then plummeted by -241bps to 0.01% in 2024, then skyrocketed by 265bps to 0.02% in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Return on Sales are 0.02% (Q4 2025), 0.02% (Q3 2025), and 0.01% (Q2 2025).